Please see below all current lung cancer clinical trials of the Central Coast Cancer Centre.
Medical oncology clinical trials
Name: BR31
A phase 3 prospective double blind placebo controlled randomized study of adjuvant medi4736 in completely resected non-small cell lung cancer.
Protocol Number: BR31
Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Lung Cancer
More information about BR31
Name: DUBLIN 3
Randomized Blinded Phase 3 Assessment of Second-or Third Line Chemotherapy with Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients with Advanced NSCLC with at Least 1 Large Lung Lesion.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Lung cancer
More information about DUBLIN 3
Radiation oncology clinical trials
Name: SABR
A Phase II Study of Stereotactic Ablative Body Radiotherapy (SABR) for Stage I NSCLC
Protocol Number: SSBROC 002
Principal Investigator: Dr Maria Azzi
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Lung cancer
More information about SABR
Name: P-Lung
A Randomised phase III trial of high dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy + HDPRT (C-HDPRT) in patients with good performance status, locally advanced / small volume metastatic NSCLC not suitable for radical Chemoradiotherapy
Protocol Number: TROG 11.03
Principal Investigator: Dr Maria Azzi
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Lung Cancer
More information about P-Lung
More information
For more information about medical oncology clinical trials please contact the Nurse Unit Manager on 02 4320 9890 or see:
Research and Clinical Trials
